CMS Approves NTAP Reimbursement for Molecular Imaging Agent Cytalux
Through a new technology add-on payment (NTAP), the use of Cytalux will reportedly be reimbursed by CMS up to 65 percent of the cost of the molecular imaging agent, which is FDA-approved for intraoperative imaging of ovarian and lung cancer.
The Centers for Medicare and Medicaid Services (CMS) has granted a new technology add-on payment for Cytalux (On Target Laboratories), an intraoperative molecular imaging agent indicated for assessment of lung and ovarian cancer.
The NTAP payment, which goes into effect on October 1, 2023, will reportedly provide hospitals with reimbursement of up to 65 percent of the cost of Cytalux with a maximum payment of $2,762.50, according to On Target Laboratories.
“We are thrilled Cytalux has been granted NTAP for both lung and ovarian cancer indications,” noted Ben Lundgren, the chief executive officer of On Target Laboratories. “This approval reinforces the clinical benefits of Cytalux and will make our technology accessible to more patients.”
On Target Laboratories noted the molecular imaging agent was granted ICD-10-PCS codes in June 2023 and recently issued a level II HCPCS code from CMS to facilitate submission of hospital claims.
(Editor’s note: For related content, see “Cytalux Gets Expanded FDA Approval for Intraoperative Imaging of Lung Cancer.”)
Can CT-Based AI Help Predict Renal Function Decline After Radioligand Therapy for mCRPC?
February 25th 2025In patients who had at least four cycles of 177Lu-PSMA-I&T for mCRPC, new research shows that a 10 percent or greater decrease in total kidney volume on CT at six months has a 90 percent AUC for predicting estimated glomerular filtration rates (eGFRs) of 30 percent or greater at one year.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.
